论文部分内容阅读
目的:研究益生菌治疗溃疡性结肠炎的疗效及其机制。方法:选择2011年2月-2015年12月在我院确诊为溃疡性结肠炎的84例患者进行研究,根据治疗方案不同随机分为观察组和对照组,观察组患者接受双歧三联活菌胶囊联合美沙拉嗪治疗,对照组患者接受美沙拉嗪治疗。结果:比较两组患者治疗前后的临床症状评分、外周血CD4~+CD25~+调节性T细胞占CD4~+T细胞的比例以及血清中白细胞介素-10的含量均高于治疗前(P<0.05);观察组患者的临床症状评分均低于对照组(P<0.05),外周血中Treg细胞占CD4~+T细胞的比例以及血清中白细胞介素-10的含量均高于对照组(P<0.05)。结论:双歧三联活菌胶囊联合美沙拉嗪治疗溃疡性结肠炎的疗效优于美沙拉嗪单药治疗,可能与其增加调节性T细胞以及抑炎因子IL-10的含量有关。
Objective: To study the efficacy and mechanism of probiotics in the treatment of ulcerative colitis. Methods: A total of 84 patients with ulcerative colitis diagnosed in our hospital from February 2011 to December 2015 were selected and randomly divided into observation group and control group according to different treatment plans. Patients in observation group received viable Bifidobacterium trifoliatum Capsules were combined with mesalazine and those in the control group received mesalazine. Results: The scores of CD4 ~ + CD25 ~ + regulatory T cells in CD4 ~ + T cells in peripheral blood and the levels of IL-10 in serum before and after treatment were significantly higher than those before treatment (P <0.05). The scores of clinical symptoms in the observation group were lower than those in the control group (P <0.05), and the percentage of Treg cells in CD4 ~ + T cells and the level of interleukin-10 in serum were higher than those in the control group (P <0.05). Conclusion: The efficacy of Bifid triple viable capsule combined with mesalazine in the treatment of ulcerative colitis is better than that of mesalazine alone, which may be related to its increase of regulatory T cells and the content of IL-10.